Liver mitochondrial DNA damage and genetic variability of Cytochrome b – a key component of the respirasome – drive the severity of fatty liver disease

C. J. Pirola1,2, M. Garaycoechea3, D. Flichman4, G. O. Castaño5 & S. Sookoian1,6

Abstract. Pirola CJ, Garaycoechea M, Flichman D, Castaño GO, Sookoian S (University of Buenos Aires, Ciudad Autónoma de Buenos Aires; Hospital de Alta Complejidad en Red ‘El Cruce’, Florencio Varela, Buenos Aires; University of Buenos Aires, Ciudad Autónoma de Buenos Aires; Hospital Abel Zubizarreta, Ciudad Autónoma de Buenos Aires; and University of Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina). Liver mitochondrial DNA damage and genetic variability of Cytochrome b – a key component of the respirasome – drive the severity of fatty liver disease (Original Article). J Intern Med 2021; 289: 84–96. https://doi.org/10.1111/joim.13147

Background and aims. The progression of nonalcoholic fatty liver disease (NAFLD) into severe histological forms (steatohepatitis – NASH) is paralleled by the occurrence of complex molecular processes. Mitochondrial dysfunction is a hallmark feature of advanced disease. Mitochondrially encoded cytochrome B (cytochrome b, MT-CYB), a member of the oxidative phosphorylation system, is a key component of the respirasome supercomplex. Here, we hypothesized that NAFLD severity is associated with liver tissue cytochrome b mutations and damaged mitochondrial DNA (mtDNA).

Methods. We included 252 liver specimens of NAFLD patients – in whom histological disease ranged from mild to severe – which were linked to clinical and biochemical information. Tissue molecular explorations included MT-CYB sequencing and analysis of differential mtDNA damage. Profiling of circulating Krebs cycle metabolites and global liver transcriptome was performed in a subsample of patients. Tissue levels of 4-hydroxynonenal – a product of lipid peroxidation and 8-hydroxy-2′-deoxyguanosine, a marker of oxidative damage – were measured.

Results. Compared to simple steatosis, NASH is associated with a higher level of MT-CYB variance, 12.1 vs. 15.6 substitutions per 103 bp (P = 5.5e-10). The burden of variants was associated with increased levels of 2-hydroxyglutarate, branched-chain amino acids, and glutamate, and changes in the global liver transcriptome. Liver mtDNA damage was associated with advanced disease and inflammation. NAFLD severity was associated with increased tissue levels of DNA oxidative adducts and lipid peroxyl radicals.

Conclusion. NASH is associated with genetic alterations of the liver cellular respirasome, including high cytochrome b variation and mtDNA damage, which may result in broad cellular effects.

Keywords: NASH, genetics, mitochondrial DNA, fibrosis, MT-CYB, transcriptome, oxidative damage.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; MT-CYB, mitochondrially encoded cytochrome b; HOMA, homoeostasis model.
Introduction

The progression of nonalcoholic fatty liver disease (NAFLD) into severe histological forms is paralleled by the occurrence of complex molecular processes that lead to a gradual loss of organ function and systemic metabolic derangement. Liver mitochondrial structural defects and mitochondrial dysfunction are the hallmark features of advanced disease [1-6]. Nonalcoholic steatohepatitis (NASH) – the distinctive severe histological disease form marked by the presence of fatty infiltration with chronic inflammation, ballooning degeneration and different degrees of fibrosis [7] – is associated with molecular alterations of the liver mitochondrial DNA (mtDNA), including epigenetic modifications [3] and complex mitochondrial genomes with high mutational rate and degree of heteroplasmy [6]. We previously demonstrated that the liver of NASH patients presents a high variation rate in genes of the five oxidative phosphorylation (OXPHOS) protein complexes, that is respiratory complexes (Complex I – IV) and ATP synthase Complex V [6].

The OXPHOS system is the main source of cell energy, as the generated electrons and protons flow across the mitochondrial membrane. This proton gradient is used for ATP synthesis. All aforementioned components of the OXPHOS complex participate in the cellular respiratory process, but four of the OXPHOS protein complexes (I to IV) associate into stable entities called respiratory supercomplexes [8,9]. In mammalian mitochondria, almost the entire Complex I is coupled with Complex III and up to four copies of Complex IV, and this network of respiratory chain complexes is known as respirasome [9]. These supercomplexes exhibit a stabilizing role in each sub-module of the respiratory complex [10], and the mitochondrially encoded cytochrome B (cytochrome b, MT-CYB) – also known as Complex III Subunit III or cytochrome b-c1 complex or ubiquinol-cytochrome c reductase complex – is a key component of the respirasome [8,9]. Mutations of the MT-CYB gene and/or mtDNA damage at the cytochrome b region may lead to severe respirasome supercomplex deficiency, and eventually to cell death in tissues that require abundant energy supply [8,9,11].

Here, we hypothesized that NAFLD severity may be driven by the accumulation of genetic alterations of the mitochondrially encoded cytochrome b within the liver tissue, including a high mutation rate and the presence of mtDNA lesions. We reasoned that exploring tissue effects across different histological stages of disease severity, as well as diverse phenotypic environments, would allow us to understand the biological implications of the impaired respirasome in NAFLD. Therefore, we examined 252 liver specimens linked to clinical and biochemical information. We further sequenced the MT-CYB gene, and we explored the presence of tissue-damaged mtDNA. In addition, we assessed the potential global metabolic effects of these molecular changes.

Subjects and methods

Study design and patient selection criteria, and physical, anthropometric and biochemical evaluation

Participants were selected from two different hospital-based settings, including a cross-sectional study of adult overweight/obese individuals patients diagnosed with NAFLD and features of the metabolic syndrome (MetS) in the Liver Unit, Hospital Abel Zubizarreta, Buenos Aires, Argentina, and an independent cohort of adult morbidly obese patients with NAFLD that underwent bariatric surgery in the Surgery Department, Hospital de Alta Complejidad en Red El Cruce, Buenos Aires, Argentina.

Inclusion criteria: Patients were considered for inclusion only if they presented: (i) histopathological evidence of NAFLD, either nonalcoholic fatty liver (NAFL) or NASH, based on a liver biopsy conducted within the study period, and (ii) available DNA isolated from the liver tissue to perform molecular explorations as explained in the Appendix S1, which was the limiting inclusion factor.

Overweight/obese individuals patients diagnosed with NAFLD were offered a percutaneous liver
biopsy if they show either abnormal aminotransferase levels (alanine and/or aspartate aminotransferase defined as > 41 units per liter [U L⁻¹]), gamma-glutamyltransferase > 50 U L⁻¹, alkaline phosphatase > 250 U L⁻¹ and/or severe insulin resistance (HOMA-IR value greater than 3).

In the case of morbidly obese cohort (bariatric surgery cohort), surgically excised liver samples were performed to all consecutive patients attending the Surgery Department, Hospital de Alta Complejidad en Red El Cruce.

Liver specimens of patients without NAFLD were included as a part of the molecular explorations. Further details can be found in the Appendix S1.

All participants (NAFLD patients and non-NAFLD patients) were selected during the same study period from the same population of patients attending the Liver Unit, and all of them share the same demographic characteristics (occupation, educational level, place of residence and ethnicity). Adopting a case–control design, we ensured that the control liver samples matched patients’ features in each cohort (morbidly obese and nonmorbidly obese).

The exclusion criteria were secondary causes of steatosis, including alcohol abuse (≥30 g alcohol daily for men and ≥ 20 g for women), total parenteral nutrition, hepatitis B and hepatitis C virus infection, and the use of drugs known to precipitate steatosis. By using standard clinical and laboratory evaluation, as well as liver biopsy features when applicable, autoimmune liver disease, metabolic liver disease, Wilson’s disease and α-1-antitrypsin deficiency were likewise ruled out in all patients.

The liver of patients with NASH exhibits high level of MT-CYB variance

Analysis of nucleotide changes in the amplified MT-CYB gene fragment per each individual enrolled in this study was performed based on the alignment with the reference sequence (NC_012920.1 Reference assembly). Median number of cumulative MT-CYB variants/mutations in the liver tissue (median 10, mean 12.56, range 5 – 66) was further used to perform the analysis of dichotomous phenotypes, such as high and low cumulative number of MT-CYB variants and variables of interest. Figure S2 shows representative sequence electropherograms sequenced by Sanger as an example.

The comparison of MT-CYB genetic variability in the liver of NAFL (12.1 variants per 1000 bp) vs. NASH patients (15.6 variants per 1000 bp) showed that the disease severity is associated with a high mutation/variation (P = 5.5e-10) rate; cumulative OR 1.30, 95% CI: 1.19 – 1.41. Likewise, analysis of liver MT-CYB sequencing revealed that the cumulative number of variants was associated with histological features, including the histological degree of steatosis (P = 3.0e-4), the lobular inflammation score (P = 8.0e-3) and the NAS score (P = 3.0e-2). Besides, cumulative number of MT-CYB mutations in liver tissue was associated with aminotransferases (ALT P = 1.9e-2 and AST P = 1.5e-2), alkaline phosphatase (P = 1.0e-10) and lactic acid (P = 2.2e-2) levels.

We further explored phenotypic features that may influence the genetic diversity of MT-CYB and found an inverse relationship between the cumulative number of MT-CYB variants and body mass index (BMI) (Spearman R = 0.40, P = 1.0e-10).
### Table 1. Clinical and biochemical features of NAFLD patients according to the disease status

| Variables                                           | NAFLD (nonalcoholic fatty liver) | NASH (nonalcoholic steatohepatitis) | *P*-value |
|-----------------------------------------------------|----------------------------------|-------------------------------------|-----------|
| **NAFLD overweight/obese patients**                 |                                  |                                     |           |
| Number of subjects                                  | 56                               | 71                                  | -         |
| Female (%)                                          | 53                               | 67                                  | NS        |
| Age, years                                          | 55 ± 11                           | 54 ± 10                             | NS        |
| BMI (body mass index), kg m⁻²                        | 31 ± 5                           | 32 ± 5                             | NS        |
| Fasting plasma glucose, mg dL⁻¹                      | 101 ± 22                         | 123 ± 43                           | 0.0007    |
| Fasting plasma insulin, μU mL⁻¹                      | 13 ± 8                           | 16 ± 10                            | 0.06      |
| HOMA-IR (homoeostatic model assessment) index       | 3.3 ± 2                          | 4.7 ± 4.3                          | 0.02      |
| HbA1c                                              | 6.5 ± 1.5                        | 7.7 ± 2.5                          | 0.0019    |
| Total cholesterol, mg dL⁻¹                           | 202 ± 41                         | 208 ± 49                           | NS        |
| HDL cholesterol, mg dL⁻¹                            | 52 ± 17                          | 50 ± 14                            | NS        |
| LDL cholesterol, mg dL⁻¹                            | 124 ± 36                         | 129 ± 41                           | NS        |
| Triglycerides, mg dL⁻¹                              | 152 ± 75                         | 173 ± 105                          | NS        |
| ALT, U L⁻¹                                          | 35 ± 17                          | 79 ± 57                            | 0.0001    |
| AST, U L⁻¹                                          | 50 ± 34                          | 52 ± 33                            | NS        |
| Degree of steatosis (0–3)                           | 1.6 ± 0.7                        | 2.2 ± 0.7                          | 0.0001    |
| Lobular inflammation (0–3)                         | 0.6 ± 0.7                        | 1.2 ± 0.7                          | 0.0001    |
| Hepatocellular ballooning (0–2)                     | 0.04 ± 0.2                       | 1 ± 1                              | 0.0001    |
| Fibrosis stage                                      | 0                                | 1.6 ± 1.3                          | 0.0001    |
| NAFLD activity score (NAS)                          | 2.6 ± 1.3                        | 4.3 ± 2                            | 0.0001    |
| **NAFLD morbidly obese patients**                   |                                  |                                     |           |
| Number of subjects                                  | 42                               | 23                                  | -         |
| Female, %                                           | 67                               | 67                                  | NS        |
| Age, years                                          | 44 ± 10                          | 46 ± 11                             | NS        |
| BMI, kg m⁻²                                        | 52 ± 12                          | 48 ± 11                             | NS        |
| Fasting plasma glucose, mg dL⁻¹                      | 108 ± 34                         | 140 ± 68                            | 0.01      |
| Fasting plasma insulin, μU mL⁻¹                      | 13 ± 7                           | 29 ± 47                            | 0.03      |
| HOMA-IR index                                       | 3.3 ± 1.8                        | 16 ± 43                             | 0.03      |
| Haemoglobin A1c (glycated haemoglobin)              | 6.6 ± 1.4                        | 6.8 ± 1.8                           | NS        |
| Total cholesterol, mg dL⁻¹                           | 182 ± 38                         | 185 ± 54                           | NS        |
| HDL cholesterol, mg dL⁻¹                            | 46 ± 10                          | 40 ± 7.5                           | 0.01      |
| LDL cholesterol, mg dL⁻¹                            | 127 ± 27                         | 132 ± 45                            | NS        |
| Triglycerides, mg dL⁻¹                              | 146 ± 52                         | 193 ± 110                          | 0.022     |
| ALT (alanine aminotransferase), U L⁻¹               | 33 ± 23                          | 44 ± 20                             | 0.058     |
| AST (aspartate aminotransferase), U L⁻¹             | 25 ± 17                          | 33 ± 16                             | 0.06      |
| Degree of steatosis, %                              | 1.6 ± 0.8                        | 2.2 ± 0.7                           | 0.0037    |
| Lobular inflammation (0–3)                          | 0.3 ± 0.6                        | 1.5 ± 0.9                           | 0.0001    |
| Hepatocellular ballooning (0–2)                      | 0.16 ± 0.4                       | 1 ± 0.6                            | 0.0001    |
| Fibrosis stage                                      | 0.02 ± 0.2                       | 1.5 ± 1.3                           | 0.0001    |
| NAFLD activity score (NAS)                          | 2 ± 1.3                          | 5 ± 1                               | 0.0001    |

Results are expressed as mean ± SD. *P*-value stands for statistical significance using the Mann–Whitney *U*-test, except for female/male proportion that *P*-value stands for statistical significance using the chi-squared test.
number of cumulative variants in the liver of morbidly obese NAFLD patients (either NAFL or NASH) was significantly lower than that obtained for NAFLD overweight/obese individuals (post hoc test for linear trend $P = 0.0007$; Slope $= 1.04$). The number of MT-CYB cumulative variants according to BMI status (morbidly obese vs. overweight/obese patients) and stages of the disease severity is shown in Figure S3. No association was found between the cumulative number of MT-CYB variants and fasting glucose, insulin, HOMA-IR and haemoglobin A1c. Complete details for every MT-CYB variant, including nucleotide position, reference SNV (rsid) identification number, alleles, gene consequence, PolyPhen prediction (if available), SIFT prediction (if available) and clinical significance (if available) are shown in Table S5.

**Rare mutations reported as pathogenic**

Using the sequencing approach described above, we searched for rare – either homoplasmic or heteroplasmic MT-CYB – mutations already reported as pathogenic in the MITOMAP (http://www.mitomap.org), OMIN (Online Mendelian Inheritance in Man) and/or CLINVAR (https://www.ncbi.nlm.nih.gov/clinvar) databases. We found four rare heteroplasmic mutations – three missense (m.G14846A, m.G15092A, and m.T15237C) and one nonsense – stop gained (m.G15242A) – and one rare (m.G15077A) homoplasmic mutation (Fig. 1a, b and Table S6). In previous studies, these mutations were shown to impair the enzymatic function of the respiratory chain cytochrome b protein (Table S6). The patient carrying the homoplasmic m.G15077A mutation was a 33-year-old woman presenting with NAFLD and severe (BMI 53) obesity. None of the patients in this series had symptoms of neuromuscular and/or extra-hepatic disorders, except for the NASH patient carrying the heteroplasmic stop gained m.15242 mutation, who presented with progressive muscle weakness and pain, recurrent headaches and vomiting. Liver MT-CYB protein expression levels in the patient carrying the nonsense mutation were severely decreased (Fig. 1c).

**Tissue-damaged mtDNA at cytochrome b region occurred more often amongst severely obese patients with advanced disease**

DNA damage or DNA fragmentation may reduce the amount of amplifiable templates; therefore, sequencing of fragmented DNA might result in loss of damaged DNA sites and might induce amplification bias in such a way that the sequenced fragments contain missing or underrepresented loci information [12]. Therefore, we reasoned that the inverse association between the cumulative number of MT-CYB variants in the liver tissue and BMI might be explained by the presence of lesions and/or breaks in the mtDNA. To test this hypothesis, we assessed the presence of liver MT-CYB damage by a validated quantitative PCR method, which relies on the relative amplification of a short and a long fragment in the same region. We found that long and short fragments were amplified with comparable efficiencies, 2.064 and 1.954, respectively.

The analysis of cytochrome b lesions revealed a significant and positive association between liver MT-CYB damage and BMI ($P = 7.9e-5$); logistic regression OR for mtDNA damage over the median: 1.04 95% CI: 1.02 – 1.07, $P = 6.6e-4$. In addition, the differential level of MT-CYB damage, which was more pronounced in the group of morbidly obese patients, was significantly associated with the disease severity ($P = 1.0e-3$) (Figure 2A). There was a significant ($P = 4.9e-2$) interaction between disease severity (NASH vs. NAFL) and population sample (overweight/moderately obese vs. morbidly obese patients), even after adjusting for age, sex and HOMA index.

Liver MT-CYB damage was also significantly associated with lobular inflammation ($P = 6.5e-3$). This association remained significant in the group of morbidly obese NAFLD patients ($P = 1.0e-3$) after adjusting for age, sex and HOMA, which was expected, as there was no association between the presence of liver MT-CYB damage and age, sex, history of type 2 diabetes and/or any biochemical parameters, including glucose, insulin or lipid-related traits.

**The burden of liver MT-CYB variants is associated with circulating levels of metabolites**

In a subsample of patients ($n = 22$), we explored the circulating level of Krebs cycle metabolites to test the hypothesis that the increased number of liver mutations in a component of the cellular respirasome supercomplex might induce global metabolic changes. We classified NAFLD patients into two groups based on the median cumulative number of MT-CYB variations ($<10$ and $\geq 10$). We found that the burden of liver MT-CYB diversity...
was significantly associated with circulating levels of 2-hydroxyglutarate, branched-chain amino acids and glutamate, amongst other metabolites (Fig. 2b).

NAFLD severity is associated with increased tissue levels of DNA oxidative adducts and lipid peroxyl radicals

We hypothesized that the liver tissue of patients with more severe histological disease presents increased levels of products of oxidative damage and lipid peroxidation, which would make mtDNA more susceptible to damage and mutation. To test this hypothesis, we measured 8-OHdG and 4-HNE levels by IHQ in the tissue samples of patients showing the full spectrum of NAFLD severity, as well as in the liver tissue of patients without evidence of NAFLD.

8-OHdG immunoreactivity product was significantly associated with the disease severity (linear test for trend $P < 0.0001$) (Fig. 3a-c and Figure S4a). Specifically, 8-OHdG immunostaining level was detected at the highest levels in the liver of NASH patients (Fig. 3a), whereas it was low in the liver of NAFL patients (Fig. 3b) and negligible in control (non-NAFLD) tissue samples (Fig. 3c). 8-OHdG-positive immunostaining was seen at both nuclear and cytoplasmic localization, which is expected because the 8-OHdG detection method stains nuclear DNA and mtDNA as well. Likewise, we found that the cumulative number of MT-CYB

**Fig. 1** Electropherograms of the MT-CYB sequencing from liver samples exhibiting rare pathogenic mutations. (a) Heteroplasmic mutations and homoplastic mutations missense mutations. Arrow indicates the location of the base changes; complete details are shown in Table S2. (b) Heteroplasmic stop gained mutation. (c) Immunohistochemical staining for MT-CYB (mutated and normal protein) in the liver tissue of NAFLD.
mutations was significantly and positively correlated with tissue levels of 8-OHdG (R 0.86, P = 4.0e-5).

Furthermore, we found that, compared with NAFL and non-NAFLD, tissue levels of 4-HNE were significantly higher in patients with NASH (Fig. 3d-f and Figure S4b). 4-HNE immunoreactivity product was significantly increased in a disease-severity grade-dependent manner from non-NAFLD (control) to NAFL to NASH (linear test for trend P = 0.0007), as shown Fig. 3d-f. 4-HNE immunostaining was exclusively localized in the cell cytoplasm, including hepatocytes and areas of active lobular and portal inflammation, suggesting that detectable levels of 4-HNE are also present in inflammatory cells (Fig. 3d). Moreover, the cumulative number of MT-CYB mutations was significantly and positively correlated with tissue levels of 4-HNE (R 0.66, P = 2.0e-2).

**Impact of the cumulative number of MT-CYB mutations/variation on the whole liver transcriptome**

In view of the numerous roles that mitochondria play in metabolically active tissues, we reasoned that multiple mutations in a member of the respirasome supercomplex would be associated with broad perturbations of cellular physiology, including changes in the full range of gene expression. To
Fig. 3  Immunohistochemical staining for 8-OHdG and 4-hydroxynonenal (4-HNE) in the liver tissue of NASH (a, d), NAFL (b, e) and non-NAFLD (c, f) patients (n = 8 per group). Asterisk indicates area shown at higher magnification in the inset (4 × amplification of the original image). Positive cells show brown staining.
assess the difference in gene expression according to the cumulative number of liver MT-CYB mutations, we explored the entire liver transcriptome.

The comparison between tissue samples of NAFLD patients with the highest cumulative number of MT-CYB mutations and the reference group (low number of cumulative mutations) showed 3291 up-regulated and 1817 down-regulated transcripts with a FDR > 0.01. The most significantly differentially expressed genes are shown in Table S7. Over-representation analysis (ORA) of genes exhibiting significantly differential expression was carried out to identify the biological processes and KEGG pathways most severely affected by the high MT-CYB mutational profile. The analysis based upon significantly up-regulated transcripts showed enrichment of pathways associated with epigenetic (chromatin and chromosome organization) and post-translational (serine phosphorylation) modifications, regulation of intracellular signal transduction, and cell cycle and migration (Fig. 4 and Table S8). Analysis based upon significantly down-regulated transcripts showed the enrichment of expected processes affected by OXPHOS chain failure, such as striated muscle contraction, as well as many critical metabolic processes, including cholesterol biosynthesis, metabolism of steroids, drug response, organic hydroxy compound metabolic process and secondary alcohol metabolic process, which includes isocitrate (an important intermediate in the TCA), ergosterol (the most important of the D provitamins that is converted to vitamin D2 upon irradiation with UV light) and vitamin D3 metabolic processes (Fig. 5 and Table S9).

**Discussion**

Complex III of the mitochondrial respiratory chain is central to the cellular energy production process. It is also the main site of ROS production, which may lead to high level of DNA damage. In this work, we described the association of histological features of NAFLD severity with the cumulative number of variants and mtDNA lesions of the mitochondrially encoded cytochrome b gene. The most remarkable feature of the present study is that molecular explorations were performed in a relatively large collection of tissue samples of NAFLD patients, which allowed us to infer a direct impact on the disease. We found that NASH, as well as features of the disease severity, including severe inflammation, was associated with high MT-CYB mutation/variation rate in the liver. The potential detrimental consequences of the high liver cytochrome b gene mutation rate seem not to be limited to the severity of histological features, as it might also affect global metabolic functioning. In the analysed samples, the burden of MT-CYB diversity was significantly associated with circulating levels of alpha-ketoglutarate/pyruvate ratio, branched-chain amino acids, glutamic acid and 2-hydroxyglutaric acid, which are known predictors of metabolic risk [13,14] and hepatic carcinogenesis [15]. Furthermore, we found that the cumulative number of MT-CYB variants was inversely correlated with BMI, which may be explained by the presence of increased mtDNA damage in morbidly obese patients.

Perturbations of mtDNA integrity and increased mutations in the mtDNA are probable consequences of oxidative injury. We found significantly increased tissue levels of DNA oxidative adducts (8-OHdG) and lipid peroxyl radicals (4-HNE). Our results are supported by earlier observations showing that (i) ROS [16] and lipid peroxidation products [17] can damage mtDNA via oxidation of guanosine to 8-OHdG and release of 4-HNE, one of the most bioactive lipid alkenals, respectively; (ii) oxidative stress-induced lesions in mtDNA can lead to somatic mutations that accumulate, affect the integrity of respiratory chain, and cause mitochondria-dependent degenerative diseases and cancer [16,18]; (iii) production of 8-OHdG is also an indicator of the presence of single-strand breaks [19]; and (iv) mitochondria are regarded as the major cellular site for ROS and 4-HNE formation [20], the latter presumably by oxidation of abundant PUFA-containing lipids [18]. It has also been suggested that mtDNA may serve as a sentinel molecule linking oxidative damage to inflammation in parenchymal cells [21]. Seki and coworkers reported that oxidative cellular damage occurs frequently in NASH, positing that it may be associated with liver fibrosis and possibly hepatocarcinogenesis [22]. Likewise, results yielded by experimental and human studies showed that the release of mitochondrial DNA molecules to the cytosol or the extracellular space triggers a pro-inflammatory response [23].

Finally, we found that the high MT-CYB mutation rate was associated with a wide range of perturbations in pathways that are linked to cancer development and metabolic deregulation. Enrichment
analysis of a set of up-regulated genes identified pathways and biological processes associated with epigenetic modifications and perturbations of cell cycle and migration, which is consistent with the concept that primary impairment of mitochondrial function via mtDNA mutations is a pervasive feature of cancer [24]. The enrichment analysis of a set of down-regulated genes identified pathways associated with cholesterol biosynthesis, particularly the transformation of zymosterol into cholesterol, which serves as the source of the 7-dehydrocholesterol for the synthesis of vitamin D.

It is worth emphasizing that mutations in any member of the OXPHOS chain can affect the functionality and operational capacity of the overall respiratory chain because the OXPHOS operates as one functional unit [25]. In fact, we have demonstrated that the expression of OXPHOS genes in the liver tissue is highly correlated [6].

It is also noteworthy that we found five likely pathogenic – either heteroplasmic or homoplasmic – MT-CYB mutations. To our knowledge, this is the first report concerning pathogenic mutations in this locus associated with NAFLD.

Each of the rare mutations reported here is reported as associated with multisystemic disorders, such as mitochondrial encephalomyopathy, stroke-like episodes (the MELAS syndrome), maternally inherited or aminoglycoside-induced deafness, exercise intolerance, cardiomyopathy, and/or liver failure [26-28]. Hitherto, mitochondrial hepatopathies have been regarded as primarily occurring in early childhood [27], with some of the

Fig. 4  Impact of the cumulative number of MT-CYB mutations/variation on the whole liver transcriptome: significantly up-regulated genes. Volcano plot based upon functional enrichment of significantly up-regulated genes of the global transcriptome. Analysis of differentially expressed pathways was based on the comparison between NAFLD patients with high cumulative number (≥10) of MT-CYB mutations/variants versus the reference group (low number of cumulative mutations, i.e. <10). Enrichment method: ORA (over-representation analysis). Further details are shown in Online Supporting Material.
affected children presenting with hepatic steatosis [26,27].

Our results suggest that NAFLD in patients carrying respiratory chain Complex III mutations in the liver tissue might be regarded as a mitochondrial hepatopathy. This is consistent with the notion that mutations in the mitochondrial genome may lead to progressive chronic degenerative processes, including tissue ageing and organ damage. However, direct confirmation of pathogenesis on mtDNA at the cell and/or tissue level is needed to fully understand the impact of the above-mentioned observations on NAFLD disease severity. The nature of our study, which included biological samples obtained by an invasive method (liver biopsy), justifies the methodological gap that exists between cause and effect in our findings. Isolation of mitochondria from fresh liver tissue to perform, for example, blue-native polyacrylamide gel electrophoresis for supercomplex analyses is technically challenging in human biological samples because it demands considerable amount of tissue.

**Limitations of the study**

Although our results based on the transcriptome and metabolic profiling are exploratory given the modest sample sizes on which the sub-studies were performed, there is remarkable consistency in the observations yielded, suggesting that an increased number of tissue mutations in the mitochondrial cytochrome b promotes a metabolic and cellular environment that generates oncogenic metabolites and initiates tumorigenesis. This mechanism might explain the development of de novo hepatocellular carcinoma in NASH patients. Nevertheless, future investigations will be needed to further explore the possibility of causal relationships amongst our findings.
In summary, much progress has been made to understand the NASH pathogenesis. Disease mechanisms involving loss of mtDNA integrity are critical not only because mtDNA is essential for mitochondrial function maintenance, but also because mtDNA regulates cell physiology. Our results highlight a novel pathogenic mechanism for understanding NAFLD severity, which may occur as the consequence of genetic alterations of the liver cellular respirasome, including respiratory chain Complex III genetic instability and mtDNA damage. The impact of MT-CYB genetic variability on NAFLD severity seems not to be related to only the number of variants in MT-CYB, but to the cumulative effects on the disease states.

Ultimately, NAFLD may exhibit the whole spectrum of a complex disease, from Mendelian syndrome-associated to the classical polygenic and multifactorial and mitochondrial forms.

Conflict of interest
Nothing to declare.

Funding
This study was partially supported by grants PICT 2015-0551 and PICT 2016-0135 (Agencia Nacional de Promoción Científica y Tecnológica, FONCyT), CONICET Proyectos Unidades Ejecutoras 2017, PUE 0055.

Authors’ contributions
CJP and SS designed research (project conception, development of overall research plan and study oversight), analysed data or performed statistical analysis, wrote paper, and had primary responsibility for final content. CJP, DF and SS conducted research (hands-on conduct of the experiments and data collection). CJP, MG, GOC and SS performed liver biopsies and/or collected biological specimens.

References
1 Caldwell SH, de Freitas LA, Park SH et al. Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 2009; 49: 1888-95.
2 Koliaki C, Szentrodedi J, Kaul K et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 2015; 21: 739-46.
3 Pirola CJ, Gianotti TF, Burgueno AL et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013; 62: 1356-63.
4 Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
5 Sookoian S, Rosselli MS, Gemma C et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology 2010; 52: 1992–2000.
6 Sookoian S, Fichman D, Scian R et al. Mitochondrial genome architecture in non-alcoholic fatty liver disease. J Pathol 2016; 240: 437-49.
7 Brunt EM, Wong VW, Nobili V et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015; 1: 15080.
8 Chaban Y, Boekema EJ, Dudkina NV. Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim Biophys Acta 2014; 1837: 418–26.
9 Schagger H, Pleifler K. Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. EMBO J 2000; 19: 1777-83.
10 Lobo-Jarne T, Ugalde C. Respiratory chain supercomplexes: Structures, function and biogenesis. Semin Cell Dev Biol 2018; 76: 179-90.
11 Acín-Perez R, Bayona-Bafaluy MP, Fernandez-Silva P et al. Respiratory complex III is required to maintain complex I in mammalian mitochondria. Mol Cell 2004; 13: 805–15.
12 Baumer C, Fisch E, Wedler H, Reinecke F, Korfhage C. Exploring DNA quality of single cells for genome analysis with simultaneous whole-genome amplification. Sci Rep 2018; 8: 7476.
13 Sookoian S, Castano GO, Scian R et al. Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level. Am J Clin Nutr 2016; 103: 422–34.
14 Yin X, Subramanian S, Willinger CM et al. Metabolite Signatures of metabolic risk factors and their longitudinal changes. J Clin Endocrinol Metab 2016; 101: 1779-89.
15 Tompkins SC, Sheldon RD, Rauchhorst AJ et al. Disrupting mitochondrial pyruvate uptake directs glutamine to the TCA Cycle away from glutathione synthesis and impairs hepatocellular tumorigenesis. Cell Rep 2019; 28: 2608–19.
16 Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2’-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci U S A 1990; 87: 4533–7.
17 Esterbauer H, Eckl P, Ortner A. Possible mutagens derived from lipids and lipid precursors. Mutat Res 1990; 238: 223–33.
18 Zhong H, Yin H. Role of lipid peroxidation derived 4-hydroxy-2-nonenal (4-HNE) in cancer: focusing on mitochondria. Redox Biol 2015; 4: 193–9.
19 Toyokuni S, Sagripanti JL. Association between 8-hydroxy-2’-deoxyguanosine formation and DNA strand breaks mediated by copper and iron. Free Radic Biol Med 1996; 20: 859–64.
20 Liu W, Porter NA, Schneider C, Brash AR, Yin H. Formation of 4-hydroxy-2-nonenal from cardiolipin oxidation: Intramolecular peroxyl radical addition and decomposition. Free Radic Biol Med 2011; 50: 166–78.
21 Szczesny B, Marcatti M, Ahmad A et al. Mitochondrial DNA damage and subsequent activation of Z-DNA binding protein 1 links oxidative stress to inflammation in epithelial cells. Sci Rep 2018; 8: 914.

22 Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37: 56–62.

23 Garcia-Martinez I, Santoro N, Chen Y et al. Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J Clin Invest 2016; 126: 859–64.

24 Gammage PA, Frezza C. Mitochondrial DNA: the overlooked oncogenome? BMC Biol 2019; 17: 53.

25 Dudkina NV, Kouril R, Peters K, Braun HP, Boekema EJ. Structure and function of mitochondrial supercomplexes. Biochim Biophys Acta 2010; 1797: 664–70.

26 Andreu AL, Hanna MG, Reichmann H et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med 1999; 341: 1037–44.

27 Lee WS, Sokol RJ. Mitochondrial hepatopathies: advances in genetics and pathogenesis. Hepatology 2007; 45: 1555–65.

28 Meunier B, Fisher N, Ransac S, Mazat JP, Brasseur G. Respiratory complex III dysfunction in humans and the use of yeast as a model organism to study mitochondrial myopathy and associated diseases. Biochim Biophys Acta 2013; 1827: 1346–61.

Correspondence: Carlos J. Pirola, PhD and Silvia Sookoian, MD, PhD, Instituto de Investigaciones Médicas, IDIM-CONICET, Combatiéntes de Malvinas 3150, CABA-1427, Argentina. (e-mails: pirola.carlos@conicet.gov.ar and ssookoian@intramed.net).

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Appendix S1. Supplemental Methods.

Figure S1. Cohorts, participants, and analyses flow chart.

Figure S2. Representative portions of mitochondrial DNA sequence electropherograms.

Figure S3. The number of MT-CYB cumulative variants according to body mass index (BMI) and stages of the disease severity (nonalcoholic fatty liver, NAFL and nonalcoholic steatohepatitis, NASH).

Figure S4. Scores of immunohistochemical staining for 8-OHdG and 4-hydroxynonenal (4-HNE) in the liver tissue.

Table S1. Primer sequences used in the analysis of MT-CYB mutations by Sanger method.

Table S2. Primer sequences used in the analysis of MT-CYB damage by Real time PCR.

Table S3. Clinical and biochemical features of the control (non-NAFLD) group.

Table S4. Clinical, biochemical, and histological features of non-morbidly obese patients with NAFLD versus morbidly obese patients with NAFLD.

Table S5. Genomic features of MT-CYB variants.

Table S6. Rare MT-CYB missense pathogenic mutations in the liver tissue of patients with NAFLD.

Table S7. Top up-regulated and down-regulated genes associated with an increased cumulative number of liver MT-CYB mutations over a list of 5969 genes.

Table S8. Over representation analysis (ORA) of GO (Gene ontology) biological processes and KEGG pathways based upon the up-regulated transcripts in the group of patients with high cumulative number of MT-CYB mutations (≥10) in comparison with the reference group (patients with low cumulative number of MT-CYB mutations < 10).

Table S9. Over representation analysis (ORA) of GO (Gene ontology) biological processes and KEGG pathways based upon the down-regulated transcripts in the group of patients with high cumulative number of MT-CYB mutations (≥10) in comparison with the reference group (patients with low cumulative number of MT-CYB mutations < 10).